<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-014090
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060405
<FILING-DATE>20060406
<DATE-OF-FILING-DATE-CHANGE>20060406
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06743748
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v039943_6-k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of April 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number 000-5112</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
              Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
              April 5, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
              Financial Officer and Company
              Secretary</em>&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                signs new evaluation agreement for cardiovascular drug
                delivery</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: ">-
          2 -</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v039943_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="psivida_logo.jpg" alt=""></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="50%"><strong><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ASX/MEDIA RELEASE</font></strong></td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5
                  April
                  2006</font></strong></div>
              </td>
            </tr>

        </table>
      </div><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      signs new evaluation agreement for </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>cardiovascular
      drug delivery</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth,
      Australia and Boston, MA - Global bio-nanotech company pSivida Limited
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(NASDAQ:PSDV,
      ASX:PSD, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      today
      announced that it has entered into an evaluation agreement with an undisclosed
      large medical device company to evaluate </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">cardiovascular
      delivery of drugs using pSivida&#8217;s drug delivery technologies.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      agreement follows the Company&#8217;s announcement in January 2006 that it had signed
      evaluation agreements </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">with
      various companies including large global pharmaceutical companies, to evaluate
      pSivida&#8217;s proprietary platform technology for their developmental compounds.
      pSivida has licensing agreements with Bausch &amp; Lomb, Alimera Sciences and
      Beijing Med-Pharm and evaluation agreements with three of the five largest
      pharmaceutical companies in the world.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      are the
      only FDA approved sustained release drug treatments to the back of the eye
      and
      both are licensed to Bausch &amp; Lomb. Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      approved by the FDA for the treatment of uveitis, a sight threatening disease
      that affects approximately 175,000 Americans. Priced at US$18,250,
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      covered by US Medicare and co-promoted in the United States by Bausch &amp; Lomb
      and Novartis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent
      results at two years from two multi-centered clinical trials in the US
      demonstrated that patients with Diabetic Macular Edema (DME) who received
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      were
      more likely to have an improvement in vision of at least three lines on an
      eye
      chart and experience a stabilization or improvement of their Diabetic
      Retinopathy (DR). There are no FDA approved drug treatments for DME and DR,
      the
      leading causes of vision loss in people under the age of 65 in the United
      States.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Unlike
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      which is
      surgically implanted into the eye, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      the
      next evolutionary stage of the technology, is designed to be injected into
      the
      eye and to release the same drug as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      at the
      same rate.&#160; Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      licensed to Alimera Sciences for the treatment of DME and is currently in phase
      III clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      licensed to Beijing Med-Pharm for China as a new and innovative treatment for
      inoperable liver cancer. BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM
      </sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      based
      on pSivida&#8217;s proprietary BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      technology and is presently in Phase IIb clinical trials conducted at Singapore
      General Hospital. We expect BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      to
      commence Phase IIa clinical trials for the treatment of inoperable pancreatic
      cancer this year.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;This</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      agreement</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      demonstrates our drug delivery technology is being evaluated in areas beyond
      ophthalmology and oncology treatments,&#8221;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      said Mr
      Gavin Rezos, CEO of pSivida Limited. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="justify" valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks; Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      conducts its operations from offices and facilities near Boston in
      Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
      Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in July 2001
      from
      the UK Government's Defence Evaluation &amp; Research Agency
      (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with it having access to its cutting edge
      research and development facilities. For more information visit
      www.QinetiQ.com</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit www.psivida.com</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties.&#160; The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases.&#160;
Although we believe that the expectations reflected in such forward-looking
      statements are reasonable at this time, we can give no assurance that such
      expectations will prove to be correct. Given these uncertainties, readers are
      cautioned not to place undue reliance on such forward-looking statements. Actual
      results could differ materially from those anticipated in these forward-looking
      statements due to many important factors including: the failure of the results
      of the Retisert for DME trial to be a good indicator </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
      the
      results of pSivida&#8217;s ongoing Phase III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Medidur&#8482;
for DME trial; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar improvement in visual acuity and diabetic
      retinopathy severity score as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for
      DME</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">;
      inability to recruit patients for the </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase
      III</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Medidur&#8482;
for DME trial; our failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
      expected revenues and the combined entity&#8217;s inability to develop existing or
      proposed products; the failure of the Bausch &amp; Lomb/Novartis co-promotion
      arrangement to provide faster royalty growth; failure of the slower progression
      or reduction of diabetic retinopathy resulting from the Retisert&#8482; implant to
      have significant implications for Retisert&#8482; and Medidur; failure of our
      evaluation agreements to result in license agreements; failure of Medidur&#8482; to
      release the same drug as Retisert&#8482; at the same rate; failure of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      in DME to show a very similar stabilization or improvement diabetic retinopathy
      as Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8482;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      for DME.
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other
      reasons are contained in cautionary statements in the Registration Statement
      on
      Form 20-F filed with the U.S. Securities and Exchange Commission, including,
      without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake
      to update any oral or written forward-looking statements that may be made by
      or
      on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida_logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0SW17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-#HP
M,R`P,3HP,3HS-0```````Z`!``,````!``$``*`"``0````!````M*`#``0`
M```!````-0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```O!````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]52253/.36P6TVBMK.6.#8)/T=S[',V)
MF7)[<#/A,N'4B-<5?X7"D"S3;25/%S+<S$+ZMK+VG:X.ES9']4CVN:J#^K9[
M,@T$5%X?LF'1,[?WE6R_$<&.&/(>(PR_)*,;L_N_WDB!-CLZ/4.IX'3,<Y.?
M>VBJ=H+N7./%=;&R^VQW^CK;O68W(^L?5CNQ:QT7!/%N0P69;QIJS$)]##;_
M`.&?6N_[K5HU^#AXESNLY=++^I`>G5:2]VT'39CLN?8S&_X7T/3WHE>3U$T.
MO86WW.&RK'`:&"P_GOOK=8YM-?\`A?S_`/KGIL4OWF'NQQ",CDD.,CT_JX]\
MGJ6&)())J(_=WDT.G?;\;ZT6=/9GWY^(S$];+&1Z;C5<]^W%;6^BNGT_6J9>
M_P!']Q=$J/2>ELZ=0\.L.1E9#S=EY3A#K;3HY^T?S=;&M]*BG_`TL96KRG1$
M4%))*CG]39AN;6UOJ6N$[9@`>94>;-CPP.3)+A@.J\`DT&\DLNGK)]8595)H
MF/<9TGC<UX;[?Y2N9MF373NQ6"RR0-I\._=JCQ\YAR8YY,9,QC^>(C+W(_\`
M4_F48D&CU;"2%C.M?0QUS=EI'O;X'\453QEQ1$A8X@#KH=4*26=U_)ZKB],L
MNZ10,K-:Y@92X2""X"S\^KZ+/Y:GT3(ZCD]+HOZI2,;->#ZU($!I#G!OYUGY
MFW\]%'%ZN'7:_!O)*KU3,.!TW*S@SU#C4ON%<[=VQI?MW>[;NVJA]5NONZ_T
MY^:Z@8Q9<ZK8'[YVACMV[:S_`$B2#,"0C?J(MV4DDDES_]#U5!RP?L[XT($R
M#'&OTMU?_5HRP^M]4R[,IG0>CN#>I7MWWY)&YN)0?:<FQOY^19]##Q_\)9^D
ML_15ILX\<91_>!C_`(R#*M4&[JCV9&-TEU;,K)M:'9-A#A140[U,QC-S_M5S
M/H54^I_/?SWZ-0L;MZCLDN+;6M+G<D@M;O=$>Y_TEK6=(;86/.1=ZK`!ZA=K
M/=W'LW?\'[%CV5N&<:M[G.%H;ZA^E,@;_P"LN=Y^&;#AP89P'##,3CR"0_6<
M4C/Y?T?F9H4297N-NSJ];>TLHJD2ZP.@F-!W[?O*WA2:`XF=Q)!G=I_6WW?]
M6J]/2JFVFYV1;;8-"[?!_JN<WW_]):"U^7P93S&3F,L?;,P(1QWQ^F/64EA(
MH`:J7!9_4_K"_P"OMW2>GYQI98T,K;:`^JN<=MUMS:=/4M9M>^ECW^GZW\Y^
MC7>KSRVVJG_&MOM>VMDM;N<0!N=B;&-EWYSWG8Q7AU\FMS!(&.C5Y(@^27I'
M4.N]'^N8Z'U#.LZACY&F^W7Z5;KZ;JV_X%VZMU-E6[TETO5J+Z<MN=6W>QNT
MGN&EO[_\ARY;-L9D?XT<84D/](L8^-8<RFZRQO\`8:_W+LLCJOV?,&/97MKT
M)MG\TCZ0;'YK_I*E\3CAEAB,TSBN4>#(!?!E_0E+^JOY4FY@>H1E(#^ZPIR>
MG=2<P7U@7-G:QW!GG:?HO1>KVVTX>^IQ8[<T2/!9G5FX;;6/Q'-WF2X5G0$1
ML<-OT7K0ZSN/3AN^EN;/Q5$<Q,X>=A+@.;%$7S&'T^[<?09&/Z<6Q0N)Z'H7
M*^L]W4V_5/[;A9-E.3C[+7V5D;G,G9:UWM=[=K_4_P"MK,SOK1F#Z@8N=7>Y
MF?>YF,;P1O#ZW.]:SCZ5E5#O^W5U5.+7F=%^R6_S>12ZI_P>"QW_`%2\FQ*L
MO+?A_5FUI;MSG"SQ#G;<?)]O_`LINL6MRNN#$3J>"!)/]UI<U*4)FB?U@,!_
M?M[;J&7UC!_Q?U9;\NW]H/%5CLB1O'JV-?L^C^;59Z7T5;Z9UK+H^H8ZO?8<
MC+KHM>'V:[GA]C*O4V[/;NV*7^,$`?57(`$`/I``_P",8LW'8Y_^*UP:)(QK
M''X-M>]W_1:INGU43*.20!/IQ?\`.<KI[?K3G_5SJ76+.JFVAU=U=N)>W>U]
M88?M#ZRW;]EL;[OL_I,V?Z1;/^+JRRGZK9=M59OLKR+G,I:0"]PKJ<VMKG>W
M<_Z*I?5_+QF_XNNI,?:QCF-R:W!Q`.ZQI]%FOYUN[]'^^B_4OJ(Z7]2NH=0+
M/4./?:]K/%VRD,:?Y._Z21Z^;'CH2QRL_P`W*1-VUWX/U_S,7,ZKG9]G378S
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MWRQSB(CP"4#Q1EDC[G"?ZL/E_P`=?$G]+0?NQ_[J3+'=CNJ`QBPU-T&P@@?Y
MJ*HU^GM_1QM_DQ$_)25F/%0XJXNM;)\E+SC,Q<3._P`:%F%F5MNHO;MLJ?J"
M/LF[_HQN:O1T#]1^U?X+[5_9]3C_`+<_FTX&F/+CX^'^K(3_`,5RNB?4[HG1
M,IV7AL>Z\@M8ZUV_8T_2;3QMW?O_`,XM7)P\?*:&W-G;]%PT(^!1TDR<(Y(F
M,XB<3O&0L+XQ$!41P^32Q^DX=#Q8UI>YIEI>9@^,*QDXU637Z5H);(.AC4(J
M2CARV&$#CCCC&$OFB!I+^\NLW=L*:F4U-J9]!@@3JLJCZJ=&Q^LNZU56X9KG
M/L)WN+-U@V6.%?T?=[O\];"2EB!$",10`H`=EIB#1(NC8:?5>EXG5L)^#F!S
MJ+"TN#7%IEI#V^YO\IJ6#TK"P>FLZ92S=B,:YGIV'?+7ESGM?O\`I[MZN)(J
MX1=UK57X/-8_^+SZLX][[A2^PN:YM;+'ES:P\%GZ&?SFM=^C?9ZGIK2Z=]7.
ME=.Z;=TNBLNP\@O-M=CB_=ZC178-SO=]!JTTDK*T8X#:(#S.+_B[^K./<ZXT
MOO)!:QMSR]K-P+?8/;[FM=[/4WK4Z)T#IW0Z;*<`/:RYP>_>\O.X`,_._JK2
M22M4<<(ZB(%/_]G_[1&R4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````
M````````````````.$))30/M```````0`$@````!``$`2`````$``3A"24T$
M)@``````#@`````````````_@```.$))300-```````$````>#A"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$`````````@`!.$))300"```````$`````#A"24T$"```````
M$`````$```)````"0``````X0DE-!!X```````0`````.$))300:``````-)
M````!@``````````````-0```+0````*`%4`;@!T`&D`=`!L`&4`9``M`#$`
M```!``````````````````````````$``````````````+0````U````````
M``````````````$`````````````````````````$`````$```````!N=6QL
M`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````U`````%)G
M:'1L;VYG````M`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI
M8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P``````
M```&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E
M9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG````-0````!29VAT;&]N9P```+0````#
M=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585```
M``$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O
M;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/
M15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0``
M``]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N
M=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L
M;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T
M;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P`
M```!/_`````````X0DE-!!0```````0````".$))300,``````O=`````0``
M`*`````O```!X```6"````O!`!@``?_8_^``$$I&248``0(!`$@`2```_^T`
M#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``O`*`#`2(``A$!`Q$!
M_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!
M`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))5,\Y-;!;3:*VLY8X-@D_1
MW/L<S8F9<GMP,^$RX=2(UQ5_A<*0+--M)4\7,MS,0OJVLO:=K@Z7-D?U2/:Y
MJH/ZMGLR#0147A^R8=$SM_>5;+\1P8X8\AXC#+\DHQNS^[_>2($V.SH]0ZG@
M=,QSDY][:*IV@NY<X\5UL;+[;'?Z.MN]9C<CZQ]6.[%K'1<$\6Y#!9EO&FK,
M0GT,-O\`X9]:[_NM6C7X.'B7.ZSETLOZD!Z=5I+W;0=-F.RY]C,;_A?0]/>B
M5Y/430Z]A;?<X;*L<!H8+#^>^^MUCFTU_P"%_/\`^N>FQ2_>8>['$(R.20XR
M/3^KCWR>I88D@DFHC]W>30Z=]OQOK19T]F??GXC,3ULL9'IN-5SW[<5M;Z*Z
M?3]:IE[_`$?W%T2H])Z6SIU#PZPY&5D/-V7E.$.MM.CG[1_-UL:WTJ*?\#2Q
ME:O*=$104DDJ.?U-F&YM;6^I:X3MF`!YE1YLV/#`Y,DN&`ZKP"30;R2RZ>LG
MUA5E4FB8]QG2>-S7AOM_E*YFV9-=.[%8++)`VGP[]VJ/'SF')CGDQDS&/YXB
M,O<C_P!3^91B0:/5L)(6,ZU]#'7-V6D>]O@?Q15/&7%$2%CB`.NAU0I)9W7\
MGJN+TRR[I%`RLUKF!E+A((+@+/SZOHL_EJ?1,CJ.3TNB_JE(QLUX/K4@0&D.
M<&_G6?F;?ST4<7JX==K\&\DJO5,PX'3<K.#/4.-2^X5SMW;&E^W=[MN[:J'U
M6Z^[K_3GYKJ!C%ESJM@?OG:&.W;MK/\`2)(,P)"-^HBW922227/_T/54'+!^
MSOC0@3(,<:_2W5_]6C+#ZWU3+LRF=!Z.X-ZE>W??DD;FXE!]IR;&_GY%GT,/
M'_PEGZ2S]%6FSCQQE']X&/\`C(,JU0;NJ/9D8W275LRLFUH=DV$.%%1#O4S&
M,W/^U7,^A53ZG\]_/?HU"QNWJ.R2XMM:TN=R2"UN]T1[G_26M9TAMA8\Y%WJ
ML`'J%VL]W<>S=_P?L6/96X9QJWN<X6AOJ'Z4R!O_`*RYWGX9L.'!AG`<,,Q.
M/()#]9Q2,_E_1^9FA1)E>XV[.KUM[2RBJ1+K`Z"8T'?M^\K>%)H#B9W$D&=V
MG];?=_U:KT]*J;:;G9%MM@T+M\'^JYS??_TEH+7Y?!E/,9.8RQ]LS`A''?'Z
M8]926$B@!JI<%G]3^L+_`*^W=)Z?G&EEC0RMMH#ZJYQVW6W-IT]2UFU[Z6/?
MZ?K?SGZ-=ZO/+;:J?\:V^U[:V2UNYQ`&YV)L8V7?G/>=C%>'7R:W,$@8Z-7D
MB#Y)>D=0Z[T?ZYCH?4,ZSJ&/D:;[=?I5NOINK;_@7;JW4V5;O272]6HOIRVY
MU;=[&[2>X:6_O_R'+ELVQF1_C1QA20_TBQCXUAS*;K+&_P!AK_<NRR.J_9\P
M8]E>VO0FV?S2/I!L?FO^DJ7Q..&6&(S3.*Y1X,@%\&7]"4OZJ_E2;F!ZA&4@
M/[K"G)Z=U)S!?6!<V=K'<&>=I^B]%ZO;;3A[ZG%CMS1(\%F=6;AMM8_$<W>9
M+A6=`1&QPV_1>M#K.X].&[Z6YL_%41S$SAYV$N`YL41?,8?3[MQ]!D8_IQ;%
M"XGH>A<KZSW=3;]4_MN%DV4Y./LM?961N<R=EK7>UWMVO]3_`*VLS.^M&8/J
M!BYU=[F9][F8QO!&\/K<[UK./I654._[=754XM>9T7[);_-Y%+JG_!X+'?\`
M5+R;$JR\M^']6;6ENW.<+/$.=MQ\GV_\"RFZQ:W*ZX,1.IX($D_W6ES4I0F:
M)_6`P']^WMNH9?6,'_%_5EOR[?V@\56.R)&\>K8U^SZ/YM5GI?15OIG6LNCZ
MACJ]]AR,NNBUX?9KN>'V,J]3;L]N[8I?XP0!]5<@`0`^D`#_`(QBS<=CG_XK
M7!HDC&L<?@VU[W?]%JFZ?51,HY)`$^G%_P`YRNGM^M.?]7.I=8LZJ;:'5W5V
MXE[=[7UAA^T/K+=OV6QON^S^DS9_I%L_XNK+*?JMEVU5F^RO(N<REI`+W"NI
MS:VN=[=S_HJE]7\O&;_BZZDQ]K&.8W)K<'$`[K&GT6:_G6[OT?[Z+]2^HCI?
MU*ZAU`L]0X]]KVL\7;*0QI_D[_I)'KYL>.A+'*S_`#<I$W;7?@_7_,Q<SJN=
MGV=-=C-=97B-(:UP8/4>UGH.<UE;6^RM]_KV6?X1;WU#Z[F]9Z38[.=ZF1C6
MFHVP&E[2UMC'/:WV^I[MKMJYC&QOV_T?-^L'UBZD;6T>HW'PP_TZ66M;^BFH
M'Z;W[?1J_G+/S[+O46M_BMG]EYL\_:!/_;;$CLG%(^["B>&<2?4;,OZS_]'T
MGK'46]+Z7E=0<W>,6IUFP?G%H]K/[3E4^K?2;>G81MS'>KU3.=]HZA>8EUKA
M_--_X'&;^@H9]!+ZPU]8]&K(Z4ZASZ"[[1C91VU6TN;ML:Y_YCJ_:]JJ"KZ[
MYXVVW8?1Z3R:`[*O^3K_`$L9G^9:BQD^K8FMNSK=1ZMT_IE3;,ZYM7J';4S5
MUECI`]/'HKW77V>[Z%3%SCGVY66;\H.PJ++`X8H=^L$$_2S+JY;A^W_M+C.^
MT_Z6^K^;6GTKIGU?Z=U%U;<AN7UM[9MMR;FVYA9'[KCOIIV_F4UU5+5'V.-/
M3CRVJIS?+'.(B/`)0/%&62/N<)_JP^7_`!U\2?TM!^['_NI,L=V.ZH#&+#4W
M0;""!_FHJC7Z>W]'&W^3$3\E)68\5#BKBZULGR4O.,S%Q,[_`!H68696VZB]
MNVRI^H(^R;O^C&YJ]'0/U'[5_@OM7]GU./\`MS^;3@:8\N/CX?ZLA/\`Q7*Z
M)]3NB=$RG9>&Q[KR"UCK7;]C3])M/&W=^_\`SBU<G#Q\IH;<V=OT7#0CX%'2
M3)PCDB8SB)Q.\9"POC$0%1'#Y-+'Z3AT/%C6E[FF6EYF#XPK&3C59-?I6@EL
M@Z&-0BI*.'+880....,82^:(&DO[RZS=VPIJ934VIGT&"!.JRJ/JIT;'ZR[K
M55;AFN<^PG>XLW6#98X5_1]WN_SUL)*6($0(Q%`"@!V6F(-$BZ-AI]5Z7B=6
MPGX.8'.HL+2X-<6F6D/;[F_RFI8/2L+!Z:SIE+-V(QKF>G8=\M>7.>U^_P"G
MNWJXDBKA%W6M5?@\UC_XO/JSCWON%+["YKFULL>7-K#P6?H9_.:UWZ-]GJ>F
MM+IWU<Z5T[IMW2Z*R[#R"\VUV.+]WJ-%=@W.]WT&K322LK1C@-H@/,XO^+OZ
MLX]SKC2^\D%K&W/+VLW`M]@]ON:UWL]3>M3HG0.G=#ILIP`]K+G![][R\[@`
MS\[^JM))*U1QPCJ(@4__V0`X0DE-!"$``````%,````!`0````\`00!D`&\`
M8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2`$$`9`!O`&(`90`@`%``:`!O
M`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE-!`8```````<`!`````$!`/_A
M%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I
M;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z>&UP=&L])UA-4"!T
M;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N-B<^"CQR9&8Z4D1&('AM;&YS
M.G)D9CTG:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R<@>&UL;G,Z:5@])VAT='`Z+R]N<RYA9&]B92YC;VTO:5@O,2XP+R<^
M"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z869D-V5E-6$M
M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS.F5X:68])VAT
M='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O)SX*("`\97AI9CI#;VQO<E-P
M86-E/C$\+V5X:68Z0V]L;W)3<&%C93X*("`\97AI9CI0:7AE;%A$:6UE;G-I
M;VX^,3@P/"]E>&EF.E!I>&5L6$1I;65N<VEO;CX*("`\97AI9CI0:7AE;%E$
M:6UE;G-I;VX^-3,\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@/"]R9&8Z1&5S
M8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z
M869D-V5E-6$M8S)C92TQ,61A+6$W-6,M.#0Y9#@Q-6%C,V-C)PH@('AM;&YS
M.G!D9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R<^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL
M;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O)SX*("`\<&AO=&]S:&]P.DAI<W1O<GD^/"]P:&]T;W-H;W`Z2&ES=&]R
M>3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIT:69F/2=H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O
M,2XP+R<^"B`@/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A=&EO
M;CX*("`\=&EF9CI84F5S;VQU=&EO;CXW,B\Q/"]T:69F.EA297-O;'5T:6]N
M/@H@(#QT:69F.EE297-O;'5T:6]N/C<R+S$\+W1I9F8Z65)E<V]L=71I;VX^
M"B`@/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI
M=#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.F%F9#=E935A+6,R8V4M,3%D82UA-S5C+3@T.60X,35A
M8S-C8R<*("!X;6QN<SIX87`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#`V+3`T+3`S5#`Q.C`Q.C,U+3`U
M.C`P/"]X87`Z0W)E871E1&%T93X*("`\>&%P.DUO9&EF>41A=&4^,C`P-BTP
M-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUO9&EF>41A=&4^"B`@/'AA<#I-
M971A9&%T841A=&4^,C`P-BTP-"TP,U0P,3HP,3HS-2TP-3HP,#PO>&%P.DUE
M=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO
M<"!#4R!7:6YD;W=S/"]X87`Z0W)E871O<E1O;VP^"B`\+W)D9CI$97-C<FEP
M=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#IA9F0W
M964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,G"B`@>&UL;G,Z>&%P
M34T])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\G/@H@(#QX87!-
M33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IA9F0W964U.2UC
M,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S8V,\+WAA<$U-.D1O8W5M96YT240^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#IA9F0W964U82UC,F-E+3$Q9&$M83<U8RTX-#ED.#$U86,S
M8V,G"B`@>&UL;G,Z9&,])VAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O)SX*("`\9&,Z9F]R;6%T/FEM86=E+VIP96<\+V1C.F9O<FUA=#X*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"CP_
M>'!A8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0
M``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'
M0@``````````````````]M8``0````#3+4A0("``````````````````````
M`````````````````````````````````````````!%C<')T```!4````#-D
M97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"&```
M`!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D```"
MQ````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M96%S
M```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```"`QB
M5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T
M+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR
M+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````````
M````````````````````````````````````````````````6%E:(```````
M`/-1``$````!%LQ865H@`````````````````````%A96B````````!OH@``
M./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$``"V
MSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````````
M``````````````````````````````!D97-C`````````"Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````
M`"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-2
M1T(`````````````````````````````9&5S8P`````````L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`
M`````````````````````````````````'9I97<``````!.D_@`47RX`$,\4
M``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``````
M```!`````````````````````````H\````"<VEG(`````!#4E0@8W5R=@``
M``````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`
M7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+
M`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!
M4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z
M`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"
MU0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3
M`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%
M#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J
M!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@(
M"P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/
M">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+
MX0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3
M#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0
MFQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#
M$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86
M219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK
M&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<
M]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8
M(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PD
MJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4
M*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M
M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J
M,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W
M8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD
M/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"
M<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+
M2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.
MMT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H
M5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<
M-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#
M8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J
M]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F
M<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[
M!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7
M@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,
M8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?
ME<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?
M'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$
MJ3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S
M.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/
MO@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(
MO,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&
MU$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?
MK^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MP
MZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX
M&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@`.061O8F4`9``````!
M_]L`A``&!`0$!00&!04&"08%!@D+"`8&"`L,"@H+"@H,$`P,#`P,#!`,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0<'!PT,#1@0$!@4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"``U`+0#`1$``A$!`Q$!_]T`!``7_\0!H@````<!`0$!`0``````````
M!`4#`@8!``<("0H+`0`"`@,!`0$!`0`````````!``(#!`4&!P@)"@L0``(!
M`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!408382)Q@10RD:$'%;%"(\%2T>$S
M%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2X@@F@PD*&!F$E$5&I+16
MTU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^A$``@(!
M`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B!G&!D3*AL?`4P='A(T(54F)R
M\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*&!DF-D4:)V1T53?RH[/#*"G3
MX_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6YO9'5V=WAY>GM\?7Y_<X
M2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!
M``(1`Q$`/P#U3BKL5=BKL5=BJ0^9O.VA>7C'!=.]QJ5QM::5:*9KN8_Y$2[T
M_P`M^*?Y6$1MHRZB,-C]7\V/U)1%;?F5KP]:YNX?*EB_]W:6Z)>7Q!_W[-)6
M")O\F..3_7P[!J`S3YGPA_IYJ?Y<:CY@EU;S/I>H:@VK6&CW<=M8ZC*B)*SF
M/G-&YC"HWI,56M,,D:6<S*42>*,3Z9?[IG.0<UV*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5__0]4XJA=1FO8;?U+2-)'4U<2,5`0`DFHKF'KLN;'CXL0C,
MCZN,\'H91`)W0FC>8(=1DDMV3TKJ+<I7DK+TY(U!49@=E=M0U4C`C@RP_AOB
MC./\_')E/'P[]$-J7F>XTYZ7.G.J,Q$<GJ*0U.^U:9B:_P!H,FE/[S#(1)/!
M+CCZ^%E#$)<BAQK.H:[:26VGQSV',B-]0A:%GBKU*B566M/\ELGV=V_/5GT8
M9<'%PSGQQ]'_`!3'-@VKBX2@;'2_+GDZ4Q:?`UYK5Y\5[J5W(9+B2O[4T[`M
M3_(7BG^3F1VKV['33&,#CRR\^"&./\Z<FG3:.,18_P!-_'),-7U77SIR6-C#
M&NOWY*6Q!+Q6\6W*ZE.WPQ@_"G^[).$>;'0SRSQ\641A+^@>+T_PL=1(CTP^
MJ7^Q_I)AY9\N6'EW1H-+LN3)'5Y9Y#62:5SRDED;]IY&/)LRR;7%B$(\(33`
MV.Q50O;ZULH#/<R".,;5.Y)\`!U.8VKUF+3PX\AX8LHQ)-!)T\[:*TG$^JJ_
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MT97D7)=BKL5?_]'U3BK3@E&`ZD$9&8L$*PBWF^J^8K2>5RB<']9WY#X55JDE
MI)30?ZV>>:0RAVEB.]S]/JXOZ4?X\N?_`'3ESK@*77_FL>9M._2%M:20:0MR
M8],NY1Q-V@3XYD0_$L7/X8R?M_:S8^VHK'C_`*TON#C:#-XED#T_P_TF1>0O
M]X+G_C+_`,:C)^QG]Q/_`(9_O0W:CF$OE,DWF34'!;DK",%>50!1:?#)$>V:
MK*93[0S2%V#P;<7]7^#+@_F_TF8V@&:K%&K,X4!V`#-W(7IOGHP<2EV*O(+K
M\^+RU\ZZGY<.A/>&SEFM[);1FDGN)HS2->'&BANKM\7!<L\/:W5'M(C(8<-T
MM\J_GGJ]SYTB\L^9]$&DS7,@@BHS\XY7%8UD5Q\0DJ`'7^;"<>UA&'M&1R<$
MX\+,O/PF_P!#._H_'\N6W\,\^]M1/]W_`#/5_I_2]!INJM::7H&K:,D-H$CN
MT1>3T_>*XZEN[`YD:7L[0Z[2"&+AAF$1ZO\`*QR?Q<?\Z/\`L6,IRC+?DG6B
M:4=,L_JWK&8<BP)%`*]0!OMG0=D]F_D\/A\7B;\7\UJR3XC:7V6O>OY@ET_Z
MLB<&D7U@?B/#Z.^:S2=L^)KI8.",>$S_`'G\7H9RQU&[8EJ7YMWVF?FC!Y-O
M--B2SN98HX=0$K<BLZ5C/`K3^\_=_:SJA#:W43UQCF\,C8_Q*GYJ?FU=>3-4
MTW3+'3DU&[OT:0H\ACXU<)&!16KS;E_P.,86G6:TX9"('$9*OYM?F!-Y/TC2
M[J72K?49KR1HY(9FHL;+'R/$\6KOMC"-IUNI\*()'%;)+;S19P>1H/,U[&+:
MU&GI?2PQ[A`8A)P3I7KQ7(UO3D1S`8A,\N'B>6:3^?/F368]0G;RK++H,*.E
MQ=67.:2W#*:&2H"/MNU.'%?BRPXP'68^TISL\'H_HI=_SBU_O?YA_P",-K_Q
M*7#E:^QN<O@RGSQ^><VE^9'\M>6=);6=4A?TIF^,KZH%6CCCC!>0I^V?AXY&
M,-K+E:CM'AGP0'')WD+\\KG6/,R^6O,>DG2=3E8QPLI<#U0.7IR1R`/&6`^$
MU;&6.A81INT3.?!,<,GK65NU?__2]4XJIW-S;VUO)<W$BPP0J9)97(55514L
MQ/0`8H)`%E@-K<IYBTY-=T*SN#:&:06KRI'%S56IS6,*&DAD_89FY?S+G%]L
M]CYL>09<$3.4)>)'@\./A_T?#CCA.?\`RLFV:;4QRQOI_2_B7>8-1N;BSM+>
M?3VL?0)"BA5"`H%$!`H!X9I.W^TLVHQPCEQ2PRB3]7%PS_J\0_XIR<.,1Y%?
MY<U:_L[.>&SL7NI)'J)%!*J>(&]!_')=A=IY\&&4,6*6:4I?5ZN"'I_BX1_O
MHIRP!.Y37R_H=T9&N;^)HY'?U'YF-N;5K]DHS(/]GFZ[%['RF1R9XF,I2\27
M'X<_$G_4\.4\?_*R+5DR#D&49V;CNQ5\Z>3O_6E-1_YBM0_Y-OETOI>?P?XX
M??+_`'S7YNJJ?GIH3H.+,VFLQ'<BY(K]PPP^E==_C,?\W_=/H/4(]/FMVAOB
MGHMU$A"[]B":;YK-=#!/&89N'@E_//"]%$D'9B&L^5[C3`;_`$^9C%%\1WI(
M@\01]H9PG:OL[/1CQ\$CP0W_`-MQ_P"=_$Y4,HEL60>5]7EU*P+3[SPMPD8;
M<MJALZCV=[4EJ\%S_O,9X)?TOYLFC-#A.R1:1_RFUQ_QDG_CG-]F?\;$_P"M
ME_2W3_NP\Z_YR3TV6QU;R_YIMA26)C`[`?MPMZ\-?^2F>DXST>8[6APRC,)<
M;F'SW^?UA+"1+IUDL$P[KPMH1.1_R/?CCRBUV,^J!_AC^/\`=)]_SE'_`,<+
M0_\`F*E_Y-8,3?VQ]$?>G7FPD?\`./`(-/\`</8C[_1&`?4W9O\`%/\`,C_O
M4%_SC^JC\K-28"A:ZN^1\:0H,.3FP[+_`+@^\_<QS_G%K_>[S#_QAM?^)2X<
MKC]C<Y?!D7F?SYY,\N>;9;+REY;BU?SI*[I-+;1A>,LGQ2*TB@O(_>4+_LY%
MR(B2-^3D9M3CQY*QQXLKSHS^9;C\]M(G\RVT-GK$E[9-/;6YJB*57TQ4,^_#
MCR^++-N'9U]S.J!F*E<7U-F.],__T_5.*O-=:DF_,'S1-Y:MG9?*.B2*?,$Z
M$CZW=*>2V:L/]UI]J?\`X'^7)C86Z_(3GGP#^[A]?]*7\QZ1##%#$D,*+'%&
MH2.-0`JJHH``.@`R#G@5LQ?S^0+2T8D!0[DD[``+U)SBO;,7CQ_UI.3I^J'_
M`"^O);FSF:UB+6;R\A>MM&X``_=#K)T^W_=_RL^9WLKHLN#!+Q!P2G+BX?X^
M'A_BC_!_G-.7,)GT[Q_G?P_YO\YF6=.Q=BKL5?+UM<^8+7\^M7N=`M([[4X;
MR^=+.5O3$J!6]1`W[+\*\/\`*R_;AW>:!F-43`<4KE^E,[#1?//GS\VK/7-5
MT2?2+.QF@><3(Z)'%:GF(P[JOJ/(X_9'[7\N)(`;8X\N?.)2CP"/^]>V^;-`
MEU!$N;4<KF$%2G3DG7:O<9QWM+V+/51&3'ODAZ>'^?#_`(J+T^')P[%)I;_S
M5<V7Z,>T<U`1Y/38.5'8L?A^G.?R:WM/-A_+''+^9*?!+CX?Z4OH_P`YM$8`
MW;(O+&CRZ98%9Z>O,W.11N%VH%KG6>SW9<M)@J?]Y,\4OZ/]%HRSXBE6F:??
M1^;I[E[>1;=GF*RE2%(-:;^^:3L_0YH]JSR&$AC,LOKX?1ZOZ39.0X*0GYS>
M6;CS#Y`OK6TA:XO[=H[JTAC')V>-J%5`ZEHV<9WD#1=3K\)R8B!S8/\`\X[^
M1-:T>^U?5M:T^:PG,<=K:)<1F-BK'G(RANWPQC)9)6X796FE`F4APIG_`,Y%
M^7M=UK1]'BTC3Y]0DAN9&E2WC:0JICH"W'IO@QFFWM7%*<1PCBW9-/Y7O=7_
M`"?B\NLA@OY=(@A$4HXE9XXE*J]?L_O%XM@OU6Y)PF6GX.O`'E7Y:7?YJZ%I
M]_Y/L_+$C/=2NPO+Q7AAMFD01NS-3A*E%#+P?_5YY9*CNZO1G/`'&(\_XI?P
MI]_SCKY6\Q:'?Z\=7TVYL4ECMU@>XC:,.4:2O'D-^HR.0@M_96&<#+B!BQ+R
M[9_F#Y`_,'4;E/+5QK4UR9H8Y5CD*2++*'$L<R*ZKRI\=?\`9<<D:(<7%'+@
MS$\)G:,7RW^95]^<.E>8-=T26+G=VDUQ);1L]O#$H4*ID'):QJ*2'E]K&QPT
MR\'-+4"<H]8OH_*'H7__U/3FKW)BM##%,D%[=AX+!I/L_6#&[I_Q`MA##(:'
MF?I2C\OO+8\L^3[#3IP$NTC];4I"P/*YE^.9F?\`:^,TY?RX9&RU:;%X>,`\
M_P"+^LE^K_FIH4-Z=*T&*3S)KAV%CIU'1#XS7']S$H_:);X?Y<1%A/61!X8_
MO)?T?^*05UY6\VZX(KOS,L%TZGG;:)`U+"`]C,6_>7LO^OQMO^*GS4]J'/0_
M+XXSR#Z<N3A_=?U(_P`]LQ83/?*=O]2C]'^?_/\`]RGN@VGF&P=DGMTDCFD5
MI)?4`*@`+L`.@`V7-/V1I^T-/(C)&.3Q9\>3)XGK_I?UG.R&!Y=&29UC0[%7
M8J\=\N?EIYLL?SHO/-=Q#$-&FGO)(Y!*I?C.C!/@Z]3EAD.&G4XM)..H,S]-
MR>Q96[9V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]7N7YP#RT?)Y&OF[$7U
MF'ZB=.%;L7>_I^B"0O*G/[1^SDH7;AZ[@\/U7S]/#]7$\P1?)ZF+_'$GG*2Q
MVX'64DCLZ?Y0@>1\LWZ4ZW]W_E/&K_;/H>T^3?\`!GZ'3_"7U/\`1G_+EQX\
MO\OC\7/_`(R?'E1OJ[?!X?#Z*K^BGN!O=BKL5=BKL5=BKL5=BKL5=BKL5=BK
1L5=BKL5=BKL5=BKL5=BK_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
